» Articles » PMID: 23292496

A Contemporary Review of Molecular Candidates for the Development and Treatment of Childhood Medulloblastoma

Overview
Specialty Pediatrics
Date 2013 Jan 8
PMID 23292496
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Medulloblastoma is the most common pediatric central nervous system tumor; however, the causes are not well established. There has been some emphasis on mutations in developmental pathways and their impact on tumor pathology in hereditary diseases, but, in order to better understand the nature of diseases like medulloblastoma, other mechanisms also require attention.

Purpose: The purpose of this review is to provide an overview of the main genes involved in neurodevelopment, their downstream targets, and modulatory links by growth factors. Occurrence of pediatric brain tumors including medulloblastoma are mostly sporadic, but some hereditary diseases like Li-Fraumeni syndrome, Gorlin's syndrome, Turcot's syndrome, and Rubenstein-Tarbi syndrome are known to contribute their development as consequences of germline mutations at specific points: DNA-repairing gene Tp53 for Li-Fraumeni syndrome or Patch for Gorlin's, and apoptosis-related gene product adenomatous polyposis coli for Turcot's disease.

Conclusion: Intracellular relations at molecular level and future therapeutics that specifically target the corresponding pathways should be well understood in order to prevent and cure childhood medulloblastoma.

Citing Articles

Magnetic Resonance Imaging Features of Common Posterior Fossa Brain Tumors in Children: A Preliminary Vietnamese Study.

Duc N, Huy H Open Access Maced J Med Sci. 2019; 7(15):2413-2418.

PMID: 31666838 PMC: 6814486. DOI: 10.3889/oamjms.2019.635.


EGF as a New Therapeutic Target for Medulloblastoma Metastasis.

Rico-Varela J, Singh T, McCutcheon S, Vazquez M Cell Mol Bioeng. 2015; 8(4):553-565.

PMID: 26594253 PMC: 4648625. DOI: 10.1007/s12195-015-0395-6.


Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells.

Ordonez R, Gallo-Oller G, Martinez-Soto S, Legarra S, Pata-Merci N, Guegan J PLoS One. 2014; 9(11):e113105.

PMID: 25392930 PMC: 4231109. DOI: 10.1371/journal.pone.0113105.


Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.

Jaeger M, Nor C, de Farias C, Abujamra A, Schwartsmann G, Brunetto A Childs Nerv Syst. 2013; 29(12):2145-50.

PMID: 24092425 DOI: 10.1007/s00381-013-2290-6.

References
1.
Packer R, Cogen P, Vezina G, RORKE L . Medulloblastoma: clinical and biologic aspects. Neuro Oncol. 2001; 1(3):232-50. PMC: 1920747. DOI: 10.1093/neuonc/1.3.232. View

2.
Yue S, Chen Y, Cheng S . Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway. Oncogene. 2008; 28(4):492-9. DOI: 10.1038/onc.2008.403. View

3.
Baryawno N, Sveinbjornsson B, Eksborg S, Chen C, Kogner P, Johnsen J . Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res. 2009; 70(1):266-76. DOI: 10.1158/0008-5472.CAN-09-0578. View

4.
Singh S, Clarke I, Hide T, Dirks P . Cancer stem cells in nervous system tumors. Oncogene. 2004; 23(43):7267-73. DOI: 10.1038/sj.onc.1207946. View

5.
Fan X, Eberhart C . Medulloblastoma stem cells. J Clin Oncol. 2008; 26(17):2821-7. PMC: 4508659. DOI: 10.1200/JCO.2007.15.2264. View